Best Practices in the Management of Hypertension in Older Adults

Similar documents
Hypertension Management Controversies in the Elderly Patient

Preventing and Treating High Blood Pressure

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Managing Hypertension in 2016

Treating Hypertension in 2018: What Makes the Most Sense Today?

Managing HTN in the Elderly: How Low to Go

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Hypertension in the very old. Objectives: Clinical Perspective

Modern Management of Hypertension

hypertension Head of prevention and control of CVD disease office Ministry of heath

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Combination Therapy for Hypertension

Objectives. Describe results and implications of recent landmark hypertension trials

T. Suithichaiyakul Cardiomed Chula

Approach to patient with hypertension. Dr. Amitesh Aggarwal

ADVANCES IN MANAGEMENT OF HYPERTENSION

Modern Management of Hypertension: Where Do We Draw the Line?

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Update in Hypertension

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

ADVANCES IN MANAGEMENT OF HYPERTENSION

The Latest Generation of Clinical

Blood Pressure Targets: Where are We Now?

5.2 Key priorities for implementation

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Jared Moore, MD, FACP

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

What s In the New Hypertension Guidelines?

Treating Hypertension in Individuals with Diabetes

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Hypertension Management: A Moving Target

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

MPharmProgramme. Hypertension (HTN)

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

Hypertension Putting the Guidelines into Practice

Diagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

Objective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

Management of Hypertension. Ahmed El Hawary MD Suez Canal University

Management of Hypertension

Difficult to Treat Hypertension

How clinically important are the results of the large trials in hypertension?

New Hypertension Guidelines. Kofi Osei, MD

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Putting the Guidelines into Practice

Hypertension and Cardiovascular Disease

Cardiac Pathophysiology

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

Blood Pressure Treatment in 2018

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to

Managing Hypertension in 2018

RESISTANT HYPERTENSION

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Egyptian Hypertension Guidelines

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

Blood Pressure Treatment Goals

Genetic factors. A number of genetic factors or interactions between genes play a major role in essential hypertension.

CKD & HT. Anne-Marie Angus

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Management of Hypertension in Women

Update on HTN and ABPM. Raj Padwal Division of General Internal Medicine University of Alberta

Diabetes and Hypertension

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

Hypertension (JNC-8)

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Management of High Blood Pressure in Adults

Prevention of Heart Failure: What s New with Hypertension

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Hypertension and Diabetes Will Controversies Help Our Patients? Insights of JNC Report Jorge De Jesús MD FACE

From the desk of the: THE VIRTUAL NEPHROLOGIST

Pharmacologic Management of Hypertension

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

How Low Do We Go? Update on Hypertension

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

Systolic Blood Pressure Intervention Trial (SPRINT)

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

What is hypertension?

Transcription:

Best Practices in the Management of Hypertension in Older Adults George Dresser, MD, PhD, FRCPC Associate Professor of Medicine Division of Clinical Pharmacology, Western U.

Speaker Disclosure Form George Dresser I have had in the past 2 years, a financial interest, arrangement or affiliation with one or more organizations that could be perceived as a direct/indirect conflict of interest in the content of the subject of this or any other program. 1. Grant / Research Support Abbott, Boehringer Ingelheim, Heart and Stroke Foundation Ontario, Merck 2. Speaker s Honorarium Abbott, Astra, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Novartis, Pfizer, and Servier

Workshop objectives 1. Discuss the rationale for changing blood pressure targets and optimal anti-hypertensive medications 2. Describe an approach to orthostatic hypotension

Proportion of Deaths Attributable to Leading Risk Factors Worldwide (2000) 0 1 2 3 4 5 6 7 8 Attributable Mortality WHO 2000 Report. Lancet. 2002;360:1347-1360.

Annual rate/1000 OXVASC community-based acute stroke and acute MI 45 40 35 30 25 20 15 10 5 0 45-54 55-64 65-74 75-84 85+ CAD CVD Rothwell PM et al. Lancet 2005

Risk factors for stroke Risk vs prevalence Hypertension 35% Hyperlipidaemia 27% Smoking 27% Percentages indicate prevalence Inactivity 27% Obesity 18% Carotid stenosis 4% Atrial fibrillation 2% 0 1 2 3 4 5 6 7 8 9 10 Alberts. Curr Med Res Opin 2003;19:438 441 Relative risk

Impact of Risk factors on Stroke Risk Prevalence % Pop. AR % Relative Risk Factor Hypertension Age 50 y 20 40 4.0 Age 60 y 30 35 3.0 Age 70 y 40 30 2.0 RRR 38% Smoking 25 12 18 1.8 50% Diabetes 7.3 5 27 1.8 6 5% Obesity 17.9 12 20 1.8 2.4 Unknown Goldstein et al. AHA/ASA Guideline: Primary Prevention of Ischemic Stroke. Circulation.2006; 113: e873-e923doi: 10.1161/

Case #1 70 yo male patient new to your practice. Presents because his blood pressure was noted to be 168/80 in the pharmacy His wife just had a stroke and is in Rehab He is asymptomatic He has no history of CV end organ damage Age of onset was likely ~ 50, no obvious secondary causes On no medications Seems motivated

Case #1 BP History Step 1: Is he symptomatic from hypertension? o Confusion o Headache o Dyspnea/CHF o Chest pain Step 2: Does he have secondary hypertension? Step 3: What can he do non-pharmacologically to help control his BP? o Salt reduction strategies o Exercise strategies o Everything else Step 4: Compelling reasons for specific pharmacotherapy

Case #1 BP Physical Step 1: Evaluate BP o In clinic: Both arms, orthostatic, and possibly the legs o Pattern assessment: repeat clinic, versus HBPM, versus ABPM Step 2: Assessment of target organ damage? o Cognitive impairment, PRES, stoke o Retinopathy o Vascular disease o LVH o Endocrine hypertension

Consider aggravating causes 2 Causes Self-inflicted Doctor-inflicted: Fate Salt Wear a white Obstructive coat (or make sleep apnea patients wait) (mimics pheo/1 Aldo biochemically) NSAIDs Not measure Consider BP correctly Hyperaldosteronism (single in those Stimulants (Street drugs/otc) measurements with/without are not low serum [K] Alcohol adequate) Intrinsic kidney disease Withdrawal reactions Give from drugs: (do a urinalysis for both blood and prescription or non-prescription Glucocorticoids drugs protein or microalbumin/cr ratio) Pain Stimulants Consider RAS in those with NSAIDs atherosclerosis Estrogens/Androgens Thyroid/Parathyroid disease Cyclosporine/EPO (measure TSH and a serum [Ca]) Nasal decongestants Consider other endocrine causes (Pheo, Cushings, Acromegaly, etc)

Back to the Case 70 yo male BP 165-170/80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Appears to be 1 Hypertension Working at salt reduction Exercise 30 min/day Why give him BP drugs? What is your goal? Can you do this safely? What drugs should you use? What is the evidence they work? How many will he need? How should they be followed up?

How I talk to the patient about BP Drugs 70 yo male BP 165-170/80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day If we get you on the right pills, and they successfully lower your BP, we can lower your risk of stroke by half, prevent heart failure, and make your life in the future better. My goal is that you get this benefit while feeling well and experiencing no side effects. I will worry about the side effects, so you don t have too.

What is the target BP? 70 yo male BP 165-170/80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day Is there an optimal BP? 130/80?? Is there an optimal drop in BP? -20/-10?? Is the BP/Benefit curve J-shaped? Harm at the lowest levels?? Should we target the systolic, or the diastolic BP, or both??

Evidence-based Annual Recommendations The Canadian Hypertension Education Program is central to Hypertension Canada CHEP is known as the most credible source for evidence-based chronic disease management recommendations with annual updates, a well-validated review process and effective dissemination techniques across Canada Canada has the world s highest reported national blood pressure control rates

CHEP 2013 Committee

The HYpertension in the Very Elderly Trial N. Beckett, R. Peters, A. Fletcher, C. Bulpitt on behalf of the HYVET committees and investigators ClinicalTrials.gov: NCT00122811

HYVET Blood pressures BP throughout trial BP target group Active Placebo SBP (mm Hg) Baseline 173 173 Achieved 143 158 Difference 30 15 DBP (mm Hg) Baseline 91 91 Achieved 78 84 Difference 13 7 Lancet. 2009 May 30; 373(9678): 1849 1860.

Blood Pressure (mmhg) Blood pressure separation 180 170 15 mmhg 160 150 140 130 120 110 100 90 80 70 Median follow-up I 1.8 years 0 1 2 3 4 5 Follow-up (years) 6 mmhg Placebo Indapamide SR +/- perindopril

All stroke (30% reduction) No. at Risk Placebo 1912 1484 807 374 194 IndapamideSR perindopril 1933 1557 873 417 229

Total Mortality (21% reduction) No. at Risk Placebo 1912 1492 814 379 202 IndapamideSR perindopril 1933 1565 877 420 231

Heart Failure (64% reduction) No. at Risk Placebo 1912 1480 794 367 188 IndapamideSR perindopril 1933 1559 872 416 228

HYVET Conclusions In a group of patients with an initial mean age of 84 and BP of 173/91, targeting an SBP < 150, and achieving a BP of 143/78, resulted in substantially better outcomes than if achieved BP is 158/84 Addition of a simple diuretic/acei combination drug to Very Elderly patients prevented problems they care about: o Heart Failure: You will end up spending hours in ER with puffy legs and the oxygen hose in your nose o Stroke o Death

Japanese Trial to Assess Optimal Systolic Blood pressure in Elderly Designed to compare target SBP < 140 to a target of 140-160 4418 Japanese patients with 1 HTN and age 65-85 enrolled in PROBE design Mean baseline blood pressure 172/89 Mean age 74 Average follow up 2 years Hypertens Res 2008; 374: 525 33

JATOS Primary outcome Hypertens Res 2008; 374: 525 33

JATOS conclusions Patients aged 65-85 (mean 74) with a baseline BP of 172/89 down to did equally well if their BP was lowered to 146/78 or 136/75 Patients under the age of 75 seemed to be better if assigned to strict control, and those over the age of 75 seemed better if assigned to mild (Hyvet style) treatment Rates of 1 Outcome Hypertens Res 2008; 374: 525 33

BP treatment in the elderly Rule out significant orthostatic BP drop If patient is over age 80, target SBP<150 If patient is under age 75, target SBP<140

CHEP Recommendation: the very elderly III. Choice of Therapy for Adults With Hypertension without Compelling Indications for Specific Agents B) Recommendations for Individuals with Isolated Systolic Hypertension New Recommendation for 2013 ADD: In the very elderly (age 80 years and older), the target for systolic BP should be < 150 mmhg (Grade C).

Back to the Case 70 yo male BP 165-170/80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day Why give him BP drugs? What is your goal? Can you do this safely? What drugs should you use? What is the evidence they work? How many will he need? How should they be followed up?

Studies of BP Drugs in the Elderly Drug Class Thiazide diuretics CCB-DHP ARB ACE-I Study SHEP, HYVET Syst-Eur MOSES, LIFE HYVET, ANBP

Case Conclusion 70 yo male BP 165-170/80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day Given that BP is > 20 mm Hg above target, he will require 2 or 3 medications My option A (No concerns about CHF or leg edema): o Start with ARB/DHP combination, half dose o If necessary add half dose diuretic My option B: o Start with ARB/ACEi in combination with diuretic o Add DHP if necessary

Case 2 80 yo male Coming home from hospital after 3 rd bad fall this year broken pelvic bone Note from medical student at hospital: He had hypertension throughout hospitalization which was attributed to pain please reassess in clinic His clinic BP s recorded 3 times over last year 135/68, 146/72, 138/70 Today it is 138/68 Two years ago another doctor tried him on amlodipine 5 mg daily he felt rotten and stopped it. He describes excessive nocturia

Case 2 80 yo male 3 rd bad fall this year Hypertension in hospital Clinic BPs 135-146/68-72 Has DM2 with mild neuropathy Taking amitriptyline 10 mg qhs and terazosin for urination Has excessive nocturia What should you do: 1. Consult psychogeriatrics 2. Consult geriatrics 3. Refer to Dr. Dresser 4. Move your office so it is up one flight of stairs 5. Cancel the rest of your clinic and do a proper assessment of postural BPs

80 yo male 3 rd bad fall this year Hypertension in hospital Clinic BPs 135-146/68-72 Has DM2 with mild neuropathy Taking amitriptyline 10 mg qhs and terazosin for urination (both started recently in hospital) Patient describes excessive nocturia Case 2 After lying supine for 5 minutes, blood pressure is recorded at 184/80 After sitting for 1 minute, BP is 138/68 After standing 1 minute, BP is 104/60 After standing 3 minutes, patient collapses with BP recorded at 94/58

ASH Position Paper: Evaluation and Treatment of Orthostatic Hypotension The Journal of Clinical Hypertension Volume 15, Issue 3, pages 147-153, 14 JAN 2013 DOI: 10.1111/jch.12062 http://onlinelibrary.wiley.com/doi/10.1111/jch.12062/full#jch12062-fig-0001

The American Journal of Medicine, Vol 120, No 10, October 2007, pp 841-847

Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia What are the goals of treatment in this man? What causes him to have nocturia? What are you more afraid of?: o Supine Grade III HTN o Standing hypotension Is it possible treat both the hypertension and the hypotension simultaneously?

Non-Drug Management Orthostatic Hypotension Withdraw offending medication (either substitution or discontinuation) Rise slowly from supine to sitting to standing position Avoid straining, coughing, and prolonged standing in hot weather Cross legs while standing Squat, stooping forward Raise head of bed 10 to 20 degrees Small meals and coffee in the morning Elastic waist high stocking Increase salt and water intake Exercise, eg, swimming, recumbent biking, and rowing The American Journal of Medicine, Vol 120, No 10, October 2007, pp 841-847

Management of Supine Hypertension/Nocturesis Raise head of bed 10 to 20 degrees Short acting antihypertensive at bed-time o Clonidine o Captopril Commode at bedside to avoid upright posture when lights are turned down/off

Drugs for Orthostatic Hypotension Drug Dose Contraindication Common Side Effects Fludrocortisone Midodrine Initial: 0.1 mg daily Max.: 1 mg daily Initial: 2.5 mg tid Max.: 10 mg tid Hypersensitivity IHD, CHF, urinary retention, thyrotoxicosis, acute renal failure Ibuprofen 400-800 mg tid Hypersensitivity to NSAIDs, active bleeding, impaired renal function Supine hypertension, hypokalemia, HF, headache Supine hypertension, piloerection, pruritus, paresthesia GI intolerance, bleeding, headache, dizziness, renal insufficiency Caffeine 100-250 mg daily Hypersensitivity GI irritation, I nsomnia, agitation,nervousness Erythropoietin 25-75 U/Kg tiw Uncontrolled hypertension Stroke, myocardial infarction, hypertension

Back to Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Goal: Improve Function! Step 1: Stop amitriptyline Step 2: Stop terazosin Step 3: Head of bed under 1 or 2 bricks Step 4: Compression stockings thigh/waist high Step 5: Clinically reassess +/- ABPM

Back to Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Goal: Improve Function! Step 6: If volume status low, fludrocortisone or water/salt Step 7: If volume up, Caffeine, then midodrine q4h prn while planning to be up must not take within 4 hours of being upright

Back to Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Goal: Improve Function! If omidodrine 10 mg TID Then ocall CMPA Midodrine should not be prescribed without careful instructions about how to use safely

80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Back to Case 2 Goal: Improve Function! If ABPM shows significant supine hypertension Then start clonidine 0.1 to 0.4mg qhs o Monitor nocturia o Alternate: Captopril 6.25 25 mg qhs All antihypertensives should be given at bed time!!

Workshop objectives 1. Discuss the rationale for changing blood pressure targets and optimal anti-hypertensive medications 2. Describe an approach to orthostatic hypotension